Published in:
Open Access
01-12-2010 | Poster presentation
Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
Authors:
E Martínez, JA Arranz, D Podzamczer, M Lonca, J Sanz, P Barragán, H Knobel, E Ribera, F Gutierrez, S Valero, B Clotet, D Dalmau, F Segura, JR Arribas, P Barrufet, I Santos, A Payeras, E de Lazzari, J Pich, J Gatell
Published in:
Journal of the International AIDS Society
|
Special Issue 4/2010
Login to get access
Excerpt
Once-daily fixed-dose combinations ABC/3TC and TDF/FTC are the preferred backbones in Europe [
1]. Long-term (>2 years) efficacy and safety of these compounds in simplification strategies are unknown. …